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Two recent articles in PLoS Medicine [1,2] criticise the role 
played by activists in raising concerns about the tenofovir 
trial for HIV prophylaxis. We fully support the fact that 
activism should be based on informed opinion, rather 
than speculation, unwarranted criticism, overreaction, or 
sensationalising facts [1], and believe that in Thailand, the 
concerns raised by activists are entirely legitimate.
The key community groups that have expressed concerns 
about the tenofovir trial in Thailand are the Thai Drug 
Users Network (TDN) and the Thai AIDS Treatment 
Advocacy Group (TTAG), which are described in Box 1. 
These community groups, which can justiﬁ  ably claim to 
represent Thai drug users, are well informed about the trial, 
but their objective concerns have been ignored by the trial 
investigators. Contrary to the assertion of Joep Lange [2] 
“that the investigators did consult intensely with community 
groups concerned”, TDN and TTAG were not consulted 
about the trial design and conduct until a very late stage, after 
several attempts to engage with the investigators had been 
rebutted. TDN and TTAG had attempted to constructively 
engage with the investigators since October 2004; they 
conﬁ  ned their statements of concern to private letters and 
meetings with the investigators, until the matter was made 
public in a Lancet editorial in March 2005 [3]. 
One major concern about the trial was the failure to provide 
sterile needles and syringes. Singh and Mills assert that this 
is consistent with Thai government policy [1]. Long prison 
terms and death sentences are the norm for drug-related 
offences [4], and Thai police, who have wide discretionary 
powers, still occasionally use possession of needles as evidence 
to arrest suspected drug users. Thus, although needles and 
syringes are available over the counter from most retail 
pharmacies, intravenous drug users (IDUs) are afraid to 
purchase them and, indeed, are often afraid to use services 
known to be provided for drug users. There is, however, no 
law or policy forbidding the distribution of clean needles and 
syringes, and preventing the investigators from doing so.
In fact, the situation in Thailand is improving, with 
the National Harm Reduction Working Group, chaired 
by the Ministry of Public Health, taking steps to increase 
activities in this domain. In 2004, at the 15th International 
AIDS Conference in Thailand, the prime minister said, 
“We are now implementing a harm reduction program 
to reduce the risk of HIV infection among injecting drug 
users…the program…will be conducted through concerted 
collaboration among solo UN agencies, government bodies 
and non-governmental organizations including the Drug User 
Network” [5]. 
The reason clean injection materials are not distributed 
within the trial is because the United States government, 
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Box 1. Community Groups Representing IDUs 
in Thailand 
Thai Drug Users Network
TDN, Thailand’s only drug users’ group, was established in 
December 2002 in response to the health and human rights 
crisis facing drug users in Thailand, particularly injectors. TDN’s 
mission is to promote the basic human rights of people who 
use drugs, in order for them to be able to live with dignity in 
Thai society. TDN undertakes peer-driven HIV prevention, care, 
and support for IDUs, has supported the Thai government 
National Harm Reduction Working Group’s activities, and has 
provided technical input to United Nations Ofﬁ  ce on Drugs and 
Crime and World Health Organization consultations. Projects 
are jointly implemented with other organisations, such as the 
project Preventing HIV and Increasing Care and Support for IDUs 
in Thailand, which is funded by the Global Fund to Fight AIDS, 
Tuberculosis, and Malaria (GFATM).
Thai AIDS Treatment Action Group
TTAG was founded in December 2002 by the founding chairman 
of the Thai Network of People Living with HIV/AIDS (PLHA) 
in order to promote leadership and advocacy among PLHA. 
TTAG’s mission is to promote equal access to AIDS prevention 
and treatment for all individuals through policy advocacy and 
coalition building, and by strengthening the capacity of people 
living with HIV/AIDS to advocate for their human rights. Projects 
include Preventing HIV and Increasing Care and Support for IDUs 
in Thailand, which is funded by GFATM, and the Mekong Region 
Treatment Preparedness Initiative.
Key Objections of TDN and TTAG to the Tenofovir Pre-
Exposure Prophylaxis Trial in Thailand in Its Present Form
• Absence of community consultation during the trial design and 
lack of meaningful consultation during its implementation.
• Best current prophylactic methods unavailable to trial 
participants.
• No commitment by trial sponsors to promote the safety of trial 
participants when accessing services.
• No commitment by the researchers to work, after the trial, with 
the Thai Ministry of Public Health towards price reductions of 
tenofovir.
Principle Recommendations 
• Urgently establish a committee, chaired by the US Centers for 
Disease Control and Prevention, to address key HIV prevention, 
treatment, and care issues for Bangkok IDUs in the context of the 
trial. Members should include two TDN representatives, and Thai 
Red Cross, government, and nongovernmental representatives.
• Involve TDN in trial outreach and education, including 
curriculum development.
• Develop partnerships to ensure the safety of trial participants 
when accessing services; for example, the Bangkok Metropolitan 
Authority should host police training workshops on harm 
reduction, and TDN should be involved in these activities.
• Commit to supporting TDN in efforts to ensure at least two 
years of post-trial tenofovir to trial participants, and to working 
with the Thai Ministry of Public Health towards price reductions.PLoS Medicine  |  www.plosmedicine.org 1045
who sponsors the trial, bans federally funded organisations 
(including the Centers for Disease Control and Prevention, 
who are overseeing the trial) from supporting needle and 
syringe exchange. 
Irrespective of whether a needle exchange exists in 
Thailand, or what the policies of the trial’s funders are 
regarding needles and syringes, investigators have a duty to 
respect the Helsinki Declaration requirement that “beneﬁ  ts, 
risks, burdens and effectiveness of a new method should 
be tested against those of the best current prophylactic, 
diagnostic and therapeutic methods” [6]. 
The HIV/AIDS community in Thailand is not naive 
about the ethics of clinical trials: many have been directly or 
indirectly affected by previous AIDS drug trials in Thailand 
that have raised ethical concerns [7,8]. Nevertheless, TDN 
and TTAG have, from the beginning, made it clear that they 
support the development of innovative prevention tools to 
reduce the burden of global HIV, and would like this trial to 
go ahead. 
We believe that the disagreements surrounding the 
tenofovir trial in Thailand would have been avoided if the 
investigators had set out to engage the community more 
openly, and if the wealth of established knowledge among 
community members could have contributed enormously 
to the success of the trial design and implementation. TDN 
and TTAG have made recommendations (see Box 1) that 
represent a constructive way for this trial to move forward. 
Mechanisms that ensure systematic involvement of legitimate 
representatives of the affected community as partners in 
research are the only way to ensure that future trials will 
proceed in a more productive way.  
Arlene Chua (msfb-bangkok@brussels.msf.org)
Nathan Ford
David Wilson
Paul Cawthorne 
Médecins Sans Frontières
Bangkok, Thailand
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Response to Joep M. A. Lange
Melissa Ditmore
Joep M. A. Lange, in his PLoS Medicine Perspective [1], 
neglected the complaints of the sex workers in the tenofovir 
trials—a lack of attention to their long-term health care, an 
appalling lack of answers to their questions about side effects, 
inadequate translation of the trial materials in some places, 
and, in past experience, a failure to deliver any new drugs to 
sex workers in the developing world once a trial is complete. 
Cambodian sex workers were offended by the assertion of 
trial conductors that they should be the bodies on which tests 
are conducted for the beneﬁ  t of the rest of the world, without 
guarantees of health care for side effects and infections that 
occur during a trial, and without even receiving answers to 
their questions about the trial. Most people in developed 
countries would have been offended if they’d been asked to 
do the same. The expectation that marginalized populations 
will accept such ungracious treatment is patently offensive. 
Sex workers would like to see research continue, and would 
like even more to see sex workers have access to effective 
treatment and prevention. Trial participants in developed 
countries have been motivated to push for faster development 
of drugs by the need for treatment. Sex workers have met 
with the organizers and supporters of the trials—this is 
extremely cooperative! Some meetings have been good and 
others have been baldfaced tokenism, some even without 
language translation. Nothing says “we don’t care what you 
have to say” louder than not translating for someone ﬂ  own 
thousands of miles to attend a meeting for two days. 
When sex workers and other marginalized people are 
genuine participants with input at all stages of research, 
they will be eager research participants. There is a good 
example of this in the journal Research for Sex Work. There 
is an update on the tenofovir trials, but the lead article is 
titled “Cambodian sex workers conduct their own research” 
[2]. These sex workers were invited to choose a topic and 
design research that would be useful for them. They did so 
because they had input into the research at every level. Drug 
researchers should take note.  
Melissa Ditmore 
Research for Sex Work 
Chiang Mai, Thailand
Network of Sex Work Projects 
Hong Kong, China
E-mail: editor@researchforsexwork.org 
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The Focus of the Media Is Medical 
Intervention, Not the Pursuit of Health
Desmond A. Gale
As the title of my response to the PLoS Medicine Debate 
[1] implies, the media know little and care less about the 
pursuit of health or about the requirements for health 
promotion, health maintenance, health protection, and 
disease prevention. Equally regrettable is the fact that very 
few journalists have the medical or scientiﬁ  c knowledge to 
qualify them to analyse and to think and write critically about 
medical policies and practices. Another shortcoming of the 
media is that their priority is not to educate and inform but to 
entertain the public. The outcome of this priority is that the 
most the public can expect from the media are meaningless 
fragments of information often calculated to confuse rather 
than enlighten them.  
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Layperson’s View
Simone Autry
In regards to the media’s dissemination of health information 
[1], I think there are the following three problems. Firstly, 
the media are shamefully sensational. Headlines can be 
misleading just to draw attention to them. Secondly, the 
media publish conﬂ  icting study reports (often going back and 
forth between conﬂ  icting ﬁ  ndings more than once). Then, 
they ﬁ  nd people to dispense advice based on these reports 
(also going back and forth multiple times) without giving 
good explanations as to why there are conﬂ  icting reports. 
Thirdly, if I were to summarize my thoughts about what I hear 
in the media, it would be that everything ﬁ  ghts cancer if it 
doesn’t kill you ﬁ  rst. What was good for you last week will kill 
you this week. There is no point, then, in following advice.  
Simone Autry 
New York, New York, United States of America
E-mail: indiratheone@yahoo.com
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We Must Find the Problem in the 
Intrinsic Mechanisms of Both Media 
and Medical Research
Luciano Benedetti
Desmond Gale is right: the media don’t care about health 
promotion and disease prevention [1,2]. In fact, this is not 
their job; the main task of the media is to inform the public 
correctly. To inform, especially about medicine and health, 
means to disseminate all relevant news, together with (and 
never without) all information needed to understand the 
facts and to use them.
I’m very concerned about the present situation of the 
medical media. I see three different problems. Firstly, 
journalists often fail to carry out this main task because they 
are forced by the media industry to produce spectacle or to 
entertain their public. Secondly, many journalists don’t know 
enough about medicine, and many scientists are unable, 
or refuse, to communicate. Some scientists, in contrast, use 
the media as a personal launch window. Thirdly, with the 
increasing privatization of research funding, many clinical 
studies are classiﬁ  ed (that is, the results, if negative, are kept 
secret by the sponsor) and often full of methodological 
bias. On the other hand, a lot of scientiﬁ  c communication is 
masked advertising.
These factors make it difﬁ  cult to achieve good health 
journalism. Fortunately, many colleagues all over the world 
(both journalists and researchers) are trying to ﬁ  nd solutions 
to these problems.  
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